The Role of Glucagon-Like Peptide-1 Receptor Agonists in Type 2 Diabetes: Understanding How Data Can Inform Clinical Practice in Korea - PubMed (original) (raw)

Review

The Role of Glucagon-Like Peptide-1 Receptor Agonists in Type 2 Diabetes: Understanding How Data Can Inform Clinical Practice in Korea

Seungjoon Oh et al. Diabetes Metab J. 2015 Jun.

Abstract

Glucagon-like peptide-1 receptor agonists (GLP-1RAs) reduce glycosylated hemoglobin (HbA1c, 0.5% to 1.0%), and are associated with moderate weight loss and a relatively low risk of hypoglycemia. There are differences between Asian and non-Asian populations. We reviewed available data on GLP-1RAs, focusing on Korean patients, to better understand their risk/benefit profile and help inform local clinical practice. Control of postprandial hyperglycemia is important in Asians in whom the prevalence of post-challenge hyperglycemia is higher (vs. non-Asians). The weight lowering effects of GLP-1RAs are becoming more salient as the prevalence of overweight and obesity among Korean patients increases. The higher rate of gastrointestinal adverse events amongst Asian patients in clinical trials may be caused by higher drug exposure due to the lower body mass index of the participants (vs. non-Asian studies). Data on the durability of weight loss, clinically important health outcomes, safety and optimal dosing in Korean patients are lacking. Use of GLP-1RAs is appropriate in several patient groups, including patients whose HbA1c is uncontrolled, especially if this is due to postprandial glucose excursions and patients who are overweight or obese due to dietary problems (e.g., appetite control). The potential for gastrointestinal adverse events should be explained to patients at treatment initiation to facilitate the promotion of better compliance.

Keywords: Clinical management; Diabetes mellitus, type 2; Glucagon-like peptide-1 receptor agonists; Glycemic control; Hyperglycemia; Postprandial period.

PubMed Disclaimer

Conflict of interest statement

CONFLICTS OF INTEREST: This work has been carried out with financial support from Sanofi Korea. The sponsor reviewed the final draft before submission. The authors acknowledge editorial assistance provided by Hazel Palmer ISMPP CMPP of Scriptix Pty Ltd.; Ms Palmer's contribution was funded by Sanofi Korea.

References

    1. Chan JC, Malik V, Jia W, Kadowaki T, Yajnik CS, Yoon KH, Hu FB. Diabetes in Asia: epidemiology, risk factors, and pathophysiology. JAMA. 2009;301:2129–2140. - PubMed
    1. Hu FB. Globalization of diabetes: the role of diet, lifestyle, and genes. Diabetes Care. 2011;34:1249–1257. - PMC - PubMed
    1. Kim SM, Lee JS, Lee J, Na JK, Han JH, Yoon DK, Baik SH, Choi DS, Choi KM. Prevalence of diabetes and impaired fasting glucose in Korea: Korean National Health and Nutrition Survey 2001. Diabetes Care. 2006;29:226–231. - PubMed
    1. Koo BK, Kim EK, Choi H, Park KS, Moon MK. Decreasing trends of the prevalence of diabetes and obesity in Korean women aged 30-59 years over the past decade: results from the Korean National Health and Nutrition Examination Survey, 2001-2010. Diabetes Care. 2013;36:e95–e96. - PMC - PubMed
    1. Kim CS, Ko SH, Kwon HS, Kim NH, Kim JH, Lim S, Choi SH, Song KH, Won JC, Kim DJ, Cha BY Taskforce Team of Diabetes Fact Sheet of the Korean Diabetes Association. Prevalence, awareness, and management of obesity in Korea: data from the Korea national health and nutrition examination survey (1998-2011) Diabetes Metab J. 2014;38:35–43. - PMC - PubMed

Publication types

LinkOut - more resources